Single-centre retrospective series on neonatal intracardiac, aortic and arterial thrombosis: Clinical presentation, therapeutic strategies and outcomes
Archives of Cardiovascular Diseases · 2025
DOI: 10.1016/j.acvd.2025.06.074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Cardiovascular Diseases, 2025. Verfasst von Mohamed Jaber und 4 weiteren Autor:innen. Beteiligte Einrichtung: M3C-Necker, Hôpital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France. Electronic address: jaber.mohamed@hotmail.fr. Hauptthemen laut MEDLINE: Thrombosis, Aortic Diseases, Heart Diseases, Anticoagulants. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Neonatal arterial thrombosis is a rare but extremely severe condition with a variable death rate. AIM: To evaluate treatment options and outcomes in a series of hyperacute presentations of intracardiac, aortic or arterial thrombosis in neonates. METHODS: All neonates with proven aortic or arterial thrombus without iatrogenic aetiology were reviewed retrospectively in a single-centre series from January 1990 to September 2023. Clinical presentation was reviewed, as well as diagnostic tools used. Treatment, outcomes and potential aetiologies were analysed. RESULTS: Seventeen neonates (six females) were identified from our database. Twelve were diagnosed between day 0 and day 1, and the rest in first week. The modes of presentation were antenatal ventricular asymmetry (n=3), cardiogenic shock (n=6), limb ischaemia (n=4), seizure (n=2) and pulmonary hypertension (n=2). The thrombus locations were thoracic aorta (n=4), abdominal aorta (n=5), coronary arteries (n=2), left atrial appendage (n=2), foramen ovale (n=1) and limb arteries (n=3). Five patients had surgical removal, four had percutaneous treatment (including thromboaspiration, thrombolysis and stent implantation) and seven had heparin infusion only. Two patients received parenteral thrombolysis. Two patients with coronary thrombosis ultimately died, one patient had limb amputation and the other patients had a complete cardiac recovery. Only one patient had a heterozygous factor V Leiden mutation as a potential thrombophilia. CONCLUSIONS: All therapeutic strategies should be discussed in multidisciplinary team, ranging from heparin infusion to surgical resection. Endovascular therapy is a valid option in a substantial number of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- M3C-Necker, Hôpital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France. Electronic address: jaber.mohamed@hotmail.fr.
- M3C-Necker, Hôpital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France.
- Inserm UMR1163, Data Science Platform, Imagine Institute, Université de Paris, 75006 Paris, France; Inserm UMR1163, Clinical Bioinformatics Group, Imagine Institute, Université Paris-Cité, 75015 Paris, France.
- M3C-Necker, Hôpital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France; Université Paris-Cité, 75006 Paris, France.
Zitieren
APA
Jaber, M., Bajolle, F., Garcelon, N., Bonnet, D., & Malekzadeh-Milani, S. (2025). Single-centre retrospective series on neonatal intracardiac, aortic and arterial thrombosis: Clinical presentation, therapeutic strategies and outcomes. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2025.06.074
Vancouver
Jaber M, Bajolle F, Garcelon N, Bonnet D, Malekzadeh-Milani S. Single-centre retrospective series on neonatal intracardiac, aortic and arterial thrombosis: Clinical presentation, therapeutic strategies and outcomes. Archives of Cardiovascular Diseases. 2025. doi:10.1016/j.acvd.2025.06.074
BibTeX
@article{Jaber2025,
author = {Jaber, Mohamed and Bajolle, Fanny and Garcelon, Nicolas and Bonnet, Damien and Malekzadeh-Milani, Sophie},
title = {Single-centre retrospective series on neonatal intracardiac, aortic and arterial thrombosis: Clinical presentation, therapeutic strategies and outcomes},
journal = {Archives of Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.acvd.2025.06.074}
}
EUVIMED